OncoMatch/Clinical Trials/NCT07104630
Pulmonary Rehabilitation in Advanced Lung Cancer Survivors
Is NCT07104630 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for non-small cell lung cancer stage iii.
This study is for people who have previously been diagnosed with advanced stage non-small cell lung cancer (NSCLC). Many people with advanced stage NSCLC have trouble breathing and feel tired. People may be eligible for this study if they have advanced stage NSCLC and feel short of breath some of the time. NSCLC survivors may also experience things like fatigue and a lower quality of life. Pulmonary rehabilitation is a type of supportive treatment that may improve these symptoms. This study has two parts. The first part is a randomized trial where half of the participants receive eight weeks of pulmonary rehabilitation. The other half of participants do not do pulmonary rehabilitation and instead receive the treatment that their doctors would normally recommend. The purpose of this part of the research study is to understand if pulmonary rehabilitation can help people with advanced stage NSCLC have better functioning and less shortness of breath. The other part of the research study is an interview study. The purpose of doing interviews is to understand any challenges or obstacles that people with advanced stage NSCLC may have regarding pulmonary rehabilitation, as well as oncology care providers have with their participants going to pulmonary rehabilitation.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–3(Limited self-care)
Lab requirements
Cardiac function
Class II, III or IV heart failure (NYHA); history of acute coronary syndromes, coronary angioplasty or stenting within past 6 months prior to radiation; uncontrolled arrhythmias (rate-controlled atrial fibrillation >1 month prior to radiation may be eligible); syncope; acute myocarditis, pericarditis, or endocarditis; suspected dissecting aneurysm; pulmonary edema; respiratory failure; acute non-cardiopulmonary disorder that may affect exercise performance or be aggravated by exercise
Any of the following cardiac exclusion criteria: Class II, III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system; history of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty or stenting within the past 6 months prior to the start of radiation therapy; uncontrolled arrhythmias; individuals with rate-controlled atrial fibrillation for > 1 month prior to start of radiation therapy may be eligible; syncope; acute myocarditis, pericarditis, or endocarditis; suspected dissecting aneurysm; pulmonary edema; respiratory failure; acute non-cardiopulmonary disorder that may affect exercise performance or be aggravated by exercise
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center · Cleveland, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify